Purple Biotech

$PPBT Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Announces CEO Transition Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Announces Plan to Implement ADS Ratio Change Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 Read the full press release here: globenewswire.com/news-release/2…

$PPBT Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress Read the full press release here: globenewswire.com/news-release/2…

We are thrilled to announce the initiation of the Phase 2 study for CM24 as a potential 2L treatment for patients with #PDAC, expanding the potential for treatment for #patients while extending our cash runway through 2024. More: tinyurl.com/522f8ccs #oncology #cancer #PDAC

We are pleased to share interim safety & efficacy in our Phase 1b Study of CM24 in Combination w/ Opdivo at #AACR22 saw 1 confirmed PR & 3 SD in patients with advanced pancreatic cancer and PTC. 9 patients still in study follow-up #oncology #Cancer bit.ly/3KxZjce

We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: bit.ly/3guxNz4 #cancerresearch #curecancer #oncology

4/4 We look forward to present an overview of our ongoing Phase 1b/2 clinical trial of CM24 at @myESMO #oncology #ESMO21

3/4 After only two treatment cycles, one patient saw a partial response of 40%, with a definite reduction of the paratracheal adenopathy and liver lesions and a 56% reduction in CA19-9 tumor marker

1/4 We are excited to provide an update about our ongoing Phase 1b/2 clinical trial of CM24 for the treatment of multiple advanced cancers #oncology #CancerResearch #PancreaticCancer bit.ly/3lgn1hS

Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer bit.ly/34OKvCQ

Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch

Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer #tasmc finance.yahoo.com/news/mechanism…

Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer